Analyzing exosomes in pancreatic cancer patients
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
This study is trying to see how tiny particles in the blood of pancreatic cancer patients compare to those in patients with non-cancer conditions to understand their role in the disease and how it might affect recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 181 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT02393703 on ClinicalTrials.gov |
What this trial studies
This study aims to isolate and analyze exosomes, which are small carriers of proteins and nucleic acids that facilitate intercellular communication. Blood and tissue samples from patients with pancreatic cancer will be compared to those from patients with benign pancreatic diseases to establish baseline 'normal' values for exosome activity. The study will investigate the relationship between exosome activity and disease recurrence and outcomes in patients. The findings will inform future research in this area.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18 and older undergoing specific surgical procedures for pancreatic cancer or benign pancreatic diseases.
Not a fit: Patients with metastatic disease or those who have received recent neoadjuvant chemotherapy or radiation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of pancreatic cancer recurrence and outcomes, potentially guiding future treatment strategies.
How similar studies have performed: While the specific approach of analyzing exosomes in this context may be novel, similar studies have shown promise in understanding cancer biology and patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients ≥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors, without an invasive component; or other benign pancreatic disease will be eligible. * For third part of the study, recipient of neoadjuvant chemotherapy will be accrued to the neoadjuvant group (25 patients). Patients without neoadjuvant chemotherapy will be accrued to the non-neoadjuvant group (25 patients). Exclusion Criteria: * The presence of metastatic disease or disease that precludes resection * For first and second part of the study, receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months of being enrolled in the study * For third part of the study, receipt of neoadjuvant radiation for the index cancer within 6 months of being enrolled in the study * INR \>2 * Known clotting factor deficiency or hypercoagulable state * Any patient with the need or anticipated need for full anti-coagulation during hospitalization for the resection. * Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to resection. * IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion for invasive component Additionally, if at the discretion of the operating surgeon, blood collection would lead to undue morbidity, the patient will be excluded and replaced
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: William Jarnagin, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: William Jarnagin, MD
- Phone: 212-639-7601
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.